All In Biotech

Drug Trial Radar · NCT05573126

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

Jan 11, 2023

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Ellipses PharmaIndustry
Sponsor type
Industry
First posted
Oct 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Conditions

  • Hormone Receptor-positive Breast Cancer
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • EP0062Drug

    EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)

  • ElacestrantDrug

    Oral SERD

  • EverolimusDrug

    mTOR Inhibitor

  • AbemaciclibDrug

    CDK4/6 inhibitor

  • FulvestrantDrug

    Oral SERD

  • ExemestaneDrug

    aromatase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) during Cycle 1 of EP0062 treatmentTime frame: first 28 days
  2. Maximum tolerated dose (MTD) and doses for evaluation in the expansion cohortsTime frame: 1 year
  3. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: up to 30 days after the end of treatment
  4. Recommended clinical (dose (s) for combination therapyTime frame: 1 year

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Yale School of Medicine

    New Haven, Connecticut · Completed

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Texas Oncology Baylor University Medical Center

    Dallas, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Hospital Universitari Vall d'Hebron (VHIO)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Recruiting

  • NEXT Oncology Hospital Quironsalud

    Madrid, Spain · Recruiting

  • Hospital 12 de Octubre

    Usera, Madrid, Spain · Recruiting

  • The Clatterbridge Cancer Centre

    Liverpool, United Kingdom · Recruiting

  • Sarah Cannon Research Institute UK

    London, London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, Wilmslow Rd, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.